Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases
This article was originally published in The Pink Sheet Daily
Switzerland's Molecular Partners extends collaboration with Janssen on novel proteins, DARPins, in immune indications.
You may also be interested in...
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.